English
Arabic
Chinese (Simplified)
Dutch
Esperanto
French
German
Greek
Italian
Japanese
Korean
Portuguese
Russian
Spanish
UrduA multi-institutional study led by UNC Lineberger Comprehensive Cancer Center researchers and colleagues has found that diagnostic mammography results varied across racial and ethnic groups, with the rate of diagnostic accuracy highest in non‐Hispanic white women and lowest in Hispanic women.
Tag: Cancer Research
The Lancet Publishes Sylvester-Led Study Defining New Standard of Care for Prostate Cancer Recurrence After Prostatectomy
Adding short-term hormone therapy and pelvic lymph node radiotherapy to standard of care prostatectomy surgical bed treatment benefits prostate cancer patients whose prostate-specific antigen (PSA) levels are rising post prostatectomy, according to an international study led by Alan Pollack, M.D.,…
Viral proteins key to tumor model in mice
A team of researchers at the University of Michigan Rogel Cancer Center were the first to generate a bona fide mouse model of a Merkel cell carcinoma, a rare and potentially aggressive form of skin cancer. The study outlining these results appeared in the Journal of Clinical Investigation.
Sylvester Researchers Study Vaginal Microbiome’s Role in Screening for Endometrial Cancer
The vaginal microbiome differentiates benign disease from endometrial cancer and can even provide insight about the specific endometrial cancer type and disease severity, according to a study by investigators at Sylvester Comprehensive Cancer Center at the University of Miami Miller School of…
What Shedding Light on Plant Growth Could Mean for Cancer
Understanding how plants process light is key to improving crop yields. Light helps plants know when to grow and flower at the right time.
Stress Protein in Fibroblasts May Be a Good Target for Future Cancer Drugs, Penn Study Finds
A stress protein that is overactive in many types of tumor cells also has a key role in tumor-supporting cells called fibroblasts, and may be a good target for future cancer treatments, suggests a study from researchers at the Perelman School of Medicine at the University of Pennsylvania.
Existing Cancer Therapy in Narrow Use Shows Significant Activity against Other Cancers
A drug currently used in just 1% of cancers has significant potential against the remaining 99%, according to a new study from UH Seidman Cancer Center and Case Western Reserve University, published in the prestigious journal Nature Cancer. Ivosidenib, or AG-120, is currently used against cancers that have a mutation in the IDH1 gene. However, study results show that Ivosidenib is also effective against unmutated, or “wild-type” IDH1. The protein coded by the IDH1 gene in cancers helps cancer cells survive in a stressful tumor environment, so any inhibitor medication that could weaken this defense mechanism is considered a promising therapy. UH and CWRU scientists discovered that under conditions present in the tumor microenvironment, drugs previously believed to be selective for the mutant enzyme have activity against the normal protein. Specifically, low glucose and magnesium levels enhance drug activity. The team has now tested Ivosidenib in mouse models of pancreatic, colorectal, o
Oral Pill Improves Care of Patients with Bone Marrow Cancer: Study
Momelotinib, an oral pill taken once a day, significantly improved outcomes of patients treated for myelofibrosis (MF), a rare but fatal bone marrow cancer, researchers reported June 7. Ruben Mesa, MD, FACP, executive director of the Mays Cancer Center, home to UT Health San Antonio MD Anderson Cancer Center, presented results of the MOMENTUM phase 3 randomized study, which evaluated momelotinib against a second medication, danazol, in symptomatic and anemic MF patients previously treated with standard-of-care JAK inhibitor therapy.
Improved progression-free survival in multiple myeloma patients following three-drug therapy with autologous stem cell transplant
Patients with multiple myeloma who have been treated with a three-drug combination therapy have a growing number of choices for subsequent treatment. Results of a new study led by researchers at Dana-Farber Cancer Institute can help patients and their physicians weigh benefits and risks of each option.
Targeted Drug Achieves 43% Response Rate in KRAS-mutated Lung Cancer
Nearly 43% of patients with non-small cell lung cancer (NSCLC) whose lung cancers harbored a specific KRAS mutation responded to the experimental drug adagrasib, and the targeted agent also showed activity against lesions in the brain that metastasized from the lung tumors, according to results of a study led by Dana-Farber Cancer Institute investigators.
Cancer Increases the Risk of Developing Diabetes
Cancer patients are at a greater risk for developing diabetes, according to a new study by the Steno Diabetes Center Copenhagen, Rigshospitalet, and the University of Copenhagen.
Sylvester Announces Transformational Cancer Research Building
Sylvester Comprehensive Cancer Center is making another bold move to accelerate cancer research, celebrating the groundbreaking for a 244,000-square-foot, state-of-the-art Sylvester Comprehensive Cancer Center – Transformational Cancer Research Building (TCRB).
High fat diet, unregulated athletic exercise endurance enhancers linked to risk of pancreatic cancer
Researchers at the University of Michigan Rogel Cancer Center have found a cell nuclear receptor activated by high fat diets and synthetic substances in unregulated athletic performance enhancers fuels the progression of precancerous pancreas lesions into pancreatic cancer.
The Paired Perils of Breast Cancer and Diabetes
UC San Diego researchers discover mechanism linking breast cancer and diabetes, each of which promotes development and growth of the other.
High Cost of Cancer Care in the U.S. Doesn’t Reduce Mortality Rates
While the U.S. spends twice as much on cancer care as the average high-income country, its cancer mortality rates are only slightly better than average, according to a new analysis by researchers at Yale University and Vassar College.
Targeted agents, combination therapies, and clinical trial equity headline Dana-Farber research at ASCO Annual Meeting
Several phase 3 studies conducted by researchers from Dana-Farber Cancer Institute show promising results for patients with multiple myeloma and breast cancer. The results of these studies, along with dozens of others led by Dana-Farber researchers, will be presented at the 2022 Annual Meeting of the American Society of Clinical Oncology (ASCO).
Internationally renowned cancer researcher joins cancer center’s leadership team
UC Davis Comprehensive Cancer Center has a new chief science officer and associate director for basic science. Xiao-Jing Wang comes from the University of Colorado Anshutz Medical Campus where she focused on skin as well as head and neck cancers
Researchers find new mechanism to turn on cancer-killing T cells
In a new study, researchers at the University of Chicago Medicine Comprehensive Cancer Center and the University of Amsterdam have brought insight into one crucial step in the anti-cancer immune response process: T cell priming.
University of Kentucky Receives Renewed $11.4 Million Grant to Further Cancer Research
The University of Kentucky’s Center for Cancer and Metabolism (CCM) will continue its critical mission to research the metabolism of cancer with a renewed Centers of Biomedical Research Excellence (COBRE) grant award from the National Institutes of General Medical Sciences, part of the National Institutes of Health.
The prestigious grant — totaling $11.4 million — will continue to fund UK’s CCM over the next five years.
New research may explain unexpected effects of common painkillers
Now, a new Yale-led study has uncovered a previously unknown process by which some NSAIDs affect the body.
Montefiore Einstein Cancer Center Researchers Receive Price Family Foundation Health Equity Research Awards
The National Cancer Institute-designated Montefiore Einstein Cancer Center (MECC) has partnered with the Price Family Foundation to fund eight research teams developing novel cancer therapies and improving cancer outcomes for historically marginalized communities in the Bronx.
Risk of breast cancer in males may be associated with male infertility
The risk of invasive breast cancer in men may be associated with self-reported infertility in the male partner finds a study published in the open-access journal Breast Cancer Research.
Groundbreaking for Major Expansion of University of Maryland Greenebaum Comprehensive Cancer Center
The University of Maryland Medical Center celebrates the groundbreaking of a nine-story patient care tower – the Roslyn and Leonard Stoler Center for Advanced Medicine – that will become the new home of the University of Maryland Marlene and Stewart Greenebaum Comprehensive Cancer Center. The $219 million building will enable the cancer center to provide the most technologically advanced, integrated care to cancer patients throughout Maryland and the region well into the future
Discovery of cell protein that keeps Kaposi’s sarcoma herpesvirus dormant
A study led by UC Davis Cancer Center identified a binding protein in cancer cell’s nucleus, known as CHD4, as a critical agent keeping Kaposi’s sarcoma-associated herpesvirus (KSHV) dormant and undetected by the body’s immune system. CHD4 is linked to cancer cell growth in many types of cancers.
Extensive Research Underway to Address Cancer Disparities
To highlight the importance of lifesaving cancer research, National Cancer Research Month, led by the American Association for Cancer Research (AACR), is recognized during May. Rutgers Cancer Institute of New Jersey together with RWJBarnabas Health, the state’s only National Cancer Institute-designated Comprehensive Cancer Center, has curated a selection of ongoing research focusing on cancer disparities which features members from the Cancer Health Equity Center of Excellence.
NCCN Foundation Announces Awards for Rising Cancer Research Leaders
National Comprehensive Cancer Network’s Oncology Research Program to oversee projects from early-career investigators advancing key areas for study in cancer care and biology, such as novel combination therapy, equitable access to cellular therapies, immune cell dysfunction, liquid biomarkers, genetic ancestry, oncogenic vulnerabilities, and MAIT cell antitumor activity.
A new pathway to shrink cancerous tumors through body’s immune cells
Cancer researchers at the Case Western Reserve University School of Medicine say they have successfully suppressed the growth of some solid tumors in research models by manipulating immune cells known as a macrophages.
How air pollution alters lung tissue, increasing cancer susceptibility
Scientists have identified a mechanism that explains how fine air pollution particles might cause lung cancer, according to a study published today in eLife.
UTSW receives new CPRIT funding to advance cancer research
The Harold C. Simmons Comprehensive Cancer Center has been awarded grants from the Cancer Prevention and Research Institute of Texas (CPRIT) to increase minority participation in clinical trials, expand lung cancer screening, develop brain tumor drugs, and advance innovations in drug discovery and technology.
A Target for Potential Cancer Drugs May, In Fact, Worsen Disease
Researchers reveal a previously unrealized complexity in cancer development, one that raises concerns and caution about targeting an enzyme popular in oncological treatments.
Twenty Years of Honoring a Legacy: Three Investigators Named Winners of Memorial Sloan Kettering Cancer Center’s 2021 Paul Marks Prize for Cancer Research
Memorial Sloan Kettering Cancer Center (MSK) is proud to announce three innovative investigators as the recipients of this year’s Paul Marks Prize for Cancer Research.
Tip Sheet: How to diversify vaccine clinical trials, 30 years of science education, Trevor Noah talks to Hutch scientists — and more
SEATTLE — Nov. 2, 2021 — Below are summaries of recent Fred Hutch research findings and other news.
UTEP Awarded $6.1 Million Grant for Cancer Research and Detection
he University of Texas at El Paso is leading new research into Hispanic cancer disparities and early cancer detection with $6.1 million in funding from the Cancer Prevention and Research Institute of Texas (CPRIT).
Albert Einstein Cancer Center Researcher Receives NCI Outstanding Investigator Award to Study Two Deadly Blood Diseases
Ulrich G. Steidl, M.D., Ph.D., co-director of the Blood Cancer Institute and associate director of basic science at the Albert Einstein Cancer Center (AECC), has received a prestigious Outstanding Investigator Award from the National Cancer Institute (NCI).
$2.1 Million Gift Launches Comprehensive Breast Cancer Database
Philanthropists Richard and Carol Dean Hertzberg have committed $2.1 million to develop and maintain the Dean-Hertzberg Breast Cancer Database System Initiative at UC San Diego Health Moores Cancer Center to support the work of Anne Wallace, MD and her collaborators at Moores Cancer Center.
Research breakthrough could mean better treatment for patients with most deadly form of brain tumor
Scientists studying the most common and aggressive type of brain tumour in adults have discovered a new way of analysing diseased and healthy cells from the same patient.
Memorial Sloan Kettering Cancer Center Announces New Early-Career Physician Research Program in Cancer Science
Memorial Sloan Kettering Cancer Center (MSK) today announced a $25 million gift from Louis V. Gerstner, Jr. to create the Louis V. Gerstner, Jr. Physician Scholars Program. Designed to support the innovative research of physician-scientists who are early in their career at MSK, the Gerstner Physician Scholars Program will advance promising scientific research and further the careers of outstanding junior faculty.
‘Research autopsy’ helps scientists study why certain cancer therapies stop working
A new research study at The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC – James) turns cancer scientists into molecular detectives, searching for clues for why certain cancers are able to spread and evolve by studying tissues collected within hours of death.
NCI renews prestigious ‘comprehensive’ designation for cancer center
The National Cancer Institute renewed the “comprehensive” designation of the UC Davis Comprehensive Cancer Center in recognition of its breadth and depth in cancer research, clinical care, cancer control and population sciences.
MD Anderson celebrates World Cancer Research Day, progress made to end cancer through research
The University of Texas MD Anderson Cancer Center is proud to support World Cancer Research Day, Sept. 24, and its efforts to promote cancer research as a driving force behind progress in cancer prevention, early detection, treatment and survivorship.
Peter Adams and Gerald Shadel awarded $13 million from NIH to study aging and liver cancer
Sanford Burnham Prebys professor Peter D. Adams, Ph.D., and Salk Institute professor Gerald Shadel, Ph.D., have been awarded a grant from the NIH’s National Institute on Aging for $13 million, funding a five-year project to explore the connection between aging and liver cancer.
Are Too Many Phase III Cancer Clinical Trials Set Up to Fail?
New research in JNCCN finds four out of five cancer therapies tested in Phase III trials do not achieve clinically-meaningful benefit in prolonging survival, and is the first study to quantify the number of false-positive, false-negative, and true-negative trial results.
Coriell Institute for Medical Research, Van Andel Institute Awarded Estimated $12.4 Million SPORE Grant from National Cancer Institute
The Coriell Institute for Medical Research and Van Andel Institute (VAI) have been awarded a prestigious Specialized Programs of Research Excellence (or SPORE) grant from the National Cancer Institute (award P50CA254897). The five-year grant valued at an estimated $12.4 million will support nearly 20 scientists as they work to improve epigenetic therapies for cancer. The project is co-led by Coriell’s President and CEO Jean-Pierre Issa, MD, Van Andel Institute’s Chief Scientific Officer Peter A. Jones, PhD, DSc (hon), and Johns Hopkins University and VAI’s Stephen Baylin, MD.
Pioneering software can grow and treat virtual tumours using AI designed nanoparticles
The EVONANO platform allows scientists to grow virtual tumours and use artificial intelligence to automatically optimise the design of nanoparticles to treat them.
UNM Cancer Center Renews NCI Comprehensive Designation
The University of New Mexico Comprehensive Cancer Center has once again been awarded the highest designation and rating in the United States for cancer treatment and research programs.
Chemical Biologist Eric Wang joins Sanford Burnham Prebys
Eric Wang, Ph.D., has joined Sanford Burnham Prebys as an assistant professor in the Tumor Initiation and Maintenance Program. Wang comes to Sanford Burnham Prebys from the Dana-Farber Cancer Institute, where he was a postdoctoral research fellow.
Johns Hopkins Cancer Researcher Ashani Weeraratna Appointed To National Cancer Advisory Board By President Biden
Johns Hopkins scientist Ashani Weeraratna, PhD, a leading cancer researcher who specializes in melanoma and the effects of aging on cancer, has been appointed by President Joe Biden to serve as a member of the National Cancer Advisory Board.
How a plant virus could protect and save your lungs from metastatic cancer
Using a virus that grows in black-eyed pea plants, researchers developed a new therapy that could keep metastatic cancers from spreading to the lungs, as well as treat established tumors in the lungs.
Researchers identify a mechanism that can help guide the development of new STING-activating drugs using imaging
A new study from scientists at the UCLA Jonsson Comprehensive Cancer Center found that emerging drugs that activate the protein STING, a well-established regulator of immune cell activation, substantially alter the activity of metabolic pathways responsible for generating the nucleotide building blocks for DNA.
Tip Sheet: Making clinical trials more inclusive, measuring COVID vaccine protection and new HIV vaccine results
SEATTLE — September 1, 2021 — Below are summaries of recent Fred Hutch research findings and other news.